04/13/2026
MAPS 2026 energized, challenged, and inspired two of our rareLife colleagues. Here are their top three takeaways, shaped by a rare disease perspective.
🔹 AI is a force multiplier, not a replacement.
A recurring theme throughout MAPS was the role of AI and the question: “Will it replace my job?” Our perspective is clear—especially in rare. AI will not replace the human insight, empathy, and community understanding required in rare disease. But agencies that don’t embrace AI will fall behind those that do. In a space where data are scarce and every insight matters, AI can help us uncover patterns faster, amplify patient voices, and accelerate development timelines. (Curious how we’re applying AI in rare? Let’s connect.)
🔹 Hands-on collaboration is critical to solving rare challenges.
The workshops stood out as powerful opportunities to engage in real-world medical affairs challenges alongside industry and agency peers. In rare disease—where patient populations are small and journeys are complex—these collaborative, applied discussions are essential. They mirror the cross-functional, community-driven approach needed to truly move the needle for patients and families.
🔹 In rare disease, continuous learning isn’t optional—it’s essential.
MAPS reinforced something we deeply believe: the learning never ends. Rare disease is constantly evolving—with new science, new voices, and new expectations. Staying curious, listening to communities, and continuously advancing how we think about science, community, and access is not optional—it’s foundational to doing this work well.
At rareLife solutions, we don’t just work in rare—we live it. And gatherings like MAPS remind us why that matters.
